What is retatrutide? The triple agonist and its trials explained

Retatrutide is Lilly’s investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. Its clinical program is testing that combination in obesity, type 2 diabetes and related complications. It remains unapproved: FDA says retatrutide is not a component of an approved drug and has not been found safe and effective for any condition.[1][4]

Reader offer · IQON Labs

Buy 1, Get 1 20% Off

Pick any two research compounds. Take 20% off the lower priced one.

20% OFF

Applied automatically at checkout, no code needed

Claim my 20% off →

In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.

This article explains clinical research, not personal treatment or product use. IQON Labs offers a separate research use only catalog that is not connected to Lilly’s trials.

One molecule with three receptor targets

An agonist activates a receptor, a protein that receives a signal and starts a response in a cell. Retatrutide is a single molecule with activity at receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. Its development code is LY3437943.[1][2]

The three targets are the reason it is called a triple agonist. The nickname “GLP-3” does not identify a third version of GLP-1; Lilly describes retatrutide by its activity at the three different receptors.[1]

GIP and GLP-1 are incretin hormones released by the gut in response to food. They help the pancreas increase insulin secretion when blood glucose is high. GLP-1 also slows stomach emptying and helps reduce appetite, linking the handling of a meal to how much a person eats.[9][11]

Glucagon has a different familiar job: it signals the liver to increase glucose output. That may sound counterintuitive in a diabetes medicine. The scientific interest is in combining its potential effects on energy use with the insulin-supporting effects of the incretins. The combination is intended to improve the overall metabolic response while managing glucagon’s tendency to raise blood sugar.[11]

A 2024 Cell Discovery paper examined retatrutide bound to each of the three receptors using cryo-electron microscopy. It also describes increased energy expenditure in obese mice. The structures establish how one molecule can engage the three receptors; human trials test what the combined activity delivers for people.[2]

What differs from semaglutide and tirzepatide

Semaglutide activates the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds glucagon receptor activity to that combination, extending the biological idea to another signal involved in energy metabolism.[2][11]

Lilly’s October 28 TRANSCEND-T2D-2 announcement compared retatrutide with injectable semaglutide, branded Ozempic, in adults with type 2 diabetes. The separate TRIUMPH-5 trial compares retatrutide with tirzepatide in adults with obesity. Its registry record lists it as active, not recruiting, with no posted results when checked for this overview.[5][6]

The TRANSCEND-T2D-2 report explains the semaglutide comparison. TRIUMPH-5 is the study to follow for the direct tirzepatide question.[6]

TRIUMPH and TRANSCEND answer different clinical questions

TRIUMPH studies retatrutide in obesity and related conditions. TRANSCEND-T2D focuses on type 2 diabetes. The programs overlap in some outcomes, but enroll different populations and do not all use the same comparator.[1][5]

TRIUMPH-1 enrolled adults with obesity without diabetes and compared retatrutide with placebo. Its primary publication reports weight reduction, with improvements in knee pain and sleep apnea measures in the subgroups assessed for those conditions.[3]

The TRIUMPH-1 results report covers the obesity trial. Separate coverage explains sleep apnea findings and TRIUMPH-4 knee osteoarthritis results. These complications give researchers outcomes beyond weight with a direct connection to daily life.

TRIUMPH-3 enrolled people with obesity and cardiovascular disease, but its registered primary outcome is change in body weight. A trial in that population does not by itself establish fewer heart attacks or strokes; cardiovascular outcomes are a separate research question in the wider program.[1][7]

Why two headlines can give different answers from one trial

A trial needs rules for events such as stopping the assigned treatment or starting another medicine. An estimand defines the treatment effect the analysis is trying to estimate, including how it handles those events.[3][5]

The TRIUMPH-1 publication uses a treatment-regimen estimand for weight outcomes, an intention-to-treat approach. Lilly’s TRANSCEND-T2D-2 release presents an efficacy estimand, estimating results had participants remained on study treatment without starting specified additional blood sugar medicines. These analyses answer different versions of the treatment question.[3][5]

The population and comparator matter too, as do the outcome and assessment time. TRIUMPH-1’s registry, for example, separates its main weight endpoint from a later endpoint for an extension subset. A longer observation in selected participants answers a different question from the main trial result.[8]

Safety and approval remain part of the answer

The TRIUMPH-1 publication identifies gastrointestinal events as the most common adverse events. Lilly’s TRANSCEND-T2D-2 release also reports digestive symptoms and dysesthesia, an altered skin sensation, and records participants stopping treatment because of adverse events. These findings belong alongside the potential benefits when evaluating the program.[3][5]

Retatrutide remains investigational. FDA’s current statement also says it cannot be used in compounding under federal law. Products offered outside Lilly’s clinical program do not acquire the trials’ evidence simply by carrying the same compound name.[1][4]

A successful trial is evidence that can support regulatory evaluation; approval requires a separate decision. Lilly says public availability depends on completing the clinical program and the regulatory process. Public availability and pricing remain unsettled while the clinical and regulatory work continues.[1]

The next useful question is which outcome improves

Retatrutide’s promise comes from testing a defined biological idea across several clinical questions. The research now extends beyond weight alone to complications that affect daily life, including sleep apnea and knee pain.[1][3]

Direct comparisons and longer follow-up will help show where that approach adds value. TRIUMPH-5 will address the specific comparison with tirzepatide, while the broader program examines whether the combined receptor activity can improve outcomes across obesity and diabetes.[1][6]